Other Events ·
CytoSorbents regains Nasdaq compliance with $1.00 minimum bid price requirement
CTSOCytosorbents Corp
CytoSorbents Corporation regained compliance with the Nasdaq Stock Market’s minimum bid price requirement of $1.00 per share as of September 22, 2026, closing a prior deficiency notice from October 2025. The company remains under a compliance deadline of December 28, 2026, to address the Minimum Value of Listed Securities (MVLS) requirement, which necessitates a market value of at least $35 million for ten consecutive business days or an increase in stockholders’ equity to $2.5 million. Management is evaluating potential actions to meet these standards and avoid delisting proceedings. CytoSorbents Corporation operates in the medical device industry, specializing in blood purification technologies for critical care applications.